Antiviral Small-Molecule Therapeutics
•21 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (21)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lagevrio is an antiviral small-molecule therapy and part of Merck's product lines.
|
$200.78B |
$79.96
-0.16%
|
|
Remdesivir and lenacapavir are antiviral small-molecule therapeutics, aligning with the Antiviral Small-Molecule Therapeutics theme.
|
$145.76B |
$117.18
-0.40%
|
|
HIV long-acting regimens involve antiviral small-molecule therapeutics, aligning with Antiviral Small-Molecule Therapeutics.
|
$88.43B |
$21.73
|
|
Cidara's lead asset CD388 is described as a long-acting antiviral (antiviral small-molecule) for universal influenza prevention/treatment, fitting the antiviral small-molecule therapeutics category.
|
$1.47B |
$113.05
-2.88%
|
|
SIGA's TPOXX is a small-molecule antiviral drug, placing the company in Antiviral Small-Molecule Therapeutics.
|
$587.25M |
$8.22
-2.72%
|
|
TEMBEXA and mpox-related antiviral efforts position Emergent in the antiviral small-molecule therapeutics space.
|
$483.62M |
$8.91
+0.45%
|
|
Atea's lead assets bemnifosbuvir and ruzasvir are oral small-molecule antivirals targeting HCV.
|
$268.72M |
$3.14
+0.32%
|
|
Enanta is actively developing antiviral small-molecule therapeutics (RSV programs and related assets), aligning with the 'Antiviral Small-Molecule Therapeutics' theme.
|
$235.57M |
$11.02
-4.26%
|
|
ASMB's core business is the discovery and development of small-molecule antiviral therapies for HSV genital herpes, HDV, and HBV, representing a distinct antiviral small-molecule therapeutics category.
|
$202.47M |
$26.51
-1.67%
|
|
TNX-4200 is a broad-spectrum antiviral small-molecule agent, a distinct antiviral small-molecule therapeutic.
|
$155.21M |
$21.19
-4.46%
|
|
HIV treatment exclusivity places ITV-1 within antiviral small-molecule therapeutics as an investable antiviral category.
|
$109.82M |
$0.32
|
|
Aligos develops small-molecule antivirals for HBV and pan-coronavirus infections, aligning with the Antiviral Small-Molecule Therapeutics investable theme.
|
$57.66M |
$9.43
-8.18%
|
|
Patented antiviral small-molecule therapeutics (MGX-0024) targeting respiratory illnesses.
|
$24.27M |
$2.20
-4.76%
|
|
DARE-HPV vaginal insert involves antiviral small-molecule therapeutics, mapping to the Antiviral Small-Molecule Therapeutics category.
|
$18.76M |
$2.12
-4.93%
|
|
Company's antiviral pipeline centers on small-molecule antivirals (ratutrelvir) targeting SARS-CoV-2.
|
$16.75M |
$3.01
-2.27%
|
|
Company is actively developing antiviral small-molecule therapeutics across influenza, norovirus/coronavirus, and HCV indications.
|
$11.70M |
$1.15
-7.26%
|
|
Preclinical assets targeting coronavirus (SACT-COV19) indicate development of antiviral small-molecule therapeutics.
|
$9.08M |
$1.66
-30.83%
|
|
Equivir G antiviral polyphenol blend; explicit antiviral small-molecule therapeutics tag.
|
$7.69M |
$0.64
+0.47%
|
|
SBFM-PL4 is described as a first-in-class antiviral protease inhibitor (PLpro) for SARS-CoV infections, a clear antiviral small-molecule program.
|
$7.06M |
$1.55
-6.63%
|
|
ProLectin-M/I/F constitute antiviral therapeutics targeting viral threats (COVID-19 and related viruses).
|
$6.67M |
$0.07
|
|
Piclidenoson's and Namodenoson's antiviral applications (e.g., COVID-19) reflect Antiviral Small-Molecule Therapeutics.
|
$2.66M |
$0.53
-7.02%
|
Loading industry metrics...
Loading comparison data...
